Engineered immune cells and a virus team up against tough cancers

NCT ID NCT05057715

Ongoing Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This early-phase trial tests a new approach for people with advanced pancreatic or ovarian cancer that has not responded to standard treatments. Participants receive a single infusion of their own immune cells, engineered to recognize and attack cancer cells (huCART-meso), along with a virus (VCN-01) designed to help the immune cells work better inside tumors. The main goal is to see if this combination is safe and feasible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: huCART-meso cells and VCN-01 virus
What this could lead to: If successful, this combination could point toward a new treatment option for hard-to-treat pancreatic and ovarian cancers.
What could go wrong: This is an early phase 1 trial with only 13 participants, focused on safety. The approach may not work or could cause severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm ovarian serous adenocarcinoma pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER SEROUS OVARIAN CANCER

Contacts and locations

Show contact details

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.